|
Plenary Lecture
Intensive Care Management of Acute Organophosphate
Insecticide Poisoning

Professor Slavica Vucinic
Clinic of Emergency and Clinical Toxicology
National Poison Control Centre
Belgrade, Serbia
E-mail:
zarkovuc@eunet.yu
Abstract:
Epidemiology: Acute
organophosphate insecticide (OPI)
poisoning is still an important
cause of morbidity and mortality,
especially in developing
countries. It is estimated that
300000 people die each year, most
of them due to deliberate OPI
poisoning. Since January 1998 till
December 2007, in Serbian National
Poison Control Centre 29723
patients were treated, among them
11174 were hospitalized. Pesticide
poisonings were registered in 526
patients. Within this group of
patients with pesticide poisoning,
OP compounds were detected in 296,
carbamates in 21, and pesticides
having other chemical structures
in 209.
Pathophysiology: Better
understanding of OPI mechanism of
action – irreversible inhibition
of acetylcholinesterase,
butyrilcholinesterase and all
esterase type enzymes, followed by
metabolic dysbalance, enforced the
development of complex therapeutic
regimens.
Therapeutic principles:
Patients with acute exposures to
organophosphorus compounds should
undergo immediate assessment and
management of disturbances in
airway, breathing, and
circulation. Further steps are
based on risk assessment and
observations during continuous
monitoring, including dose
ingested, time since ingestion,
clinical features, patient
factors, and available medical
facilities. Patients with moderate
or severe organophosphorus
poisoning should be admitted to an
intensive care unit after
resuscitation in order to provide
careful titration of antidotes,
intubation, ventilation, and
inotropes or vasopressors if
required. Careful observation is
also required because rapid
clinical deterioration and death
are reported in patients who
seemed to be recovering from the
acute cholinergic crisis. High
quality intensive medical care is
a priority as hospital stay may be
prolonged, with secondary
complications which are an
important cause of morbidity and
mortality.
Current therapeutic scheme
for management of acute poisoning
with anticholinesterase pesticides
includes general supportive
measures (decontamination,
respiratory support) and specific
pharmacological treatment
(atropine, oxime, diazepam).
Gastric lavage is the most
commonly used form of
decontamination in OP poisoning.
Since the rate of absorption of OP
containing P=O bond from the human
bowel is rapid, as indicated by
the appearance of symptoms of OP
poisoning within a few minutes,
gastric lavage should be performed
as soon as possible, preferably
within 2 hours post ingestion.
Administration of oral activated
charcoal, in conventional doses,
may be considered for reducing
further absorption of OP
pesticides. However, recent
clinical trials designed to
evaluate the effectiveness of
single and multiple doses of
activated charcoal failed to find
a significant benefit of either
regimen over placebo. Atropine is
the mainstay of treatment of
effects mediated by muscarinic
sensitive receptors, but it is
ineffective at the nicotine
sensitive synapses, it has limited
antimuscarinic effects in CNS and
counteracting of convulsions is
possible only immediately after
exposure. Some toxicologists
prefer glycopyrrolate and hyoscine
(scopolamine) methylbromide: These
agents do not enter the CNS and
they are not effective against
coma and reduced respiratory drive
in patients with
anticholinesterase poisoning.
Diazepam is used in counteracting
convulsions, and it also improves
atropine tolerance, reduces
central nervous system damage and
central respiratory weakness.
Oximes reactivate phosphorylated
AChE by displacing the phosphoryl
moiety from the enzyme by virtue
of their high affinity for the
enzyme and their powerful
nucleophilicity. The rate of
reactivation depends on the
structure of the phosphoryl moiety
bound to the enzyme, the source of
the enzyme, the structure and
concentration of oxime which is
present at the active site, and
the rate of aging. Several oximes
have been developed, but two (Pralidoxime
chloride and Obidoxime) are more
commonly used for acute
organophosphorus poisoning. They
are administered as an infusion
which continues until recovery.
Serbian NPCC experience:
During the different phases of
development of the NPCC in
Belgrade, many pyridinium oximes
were used in experimental and
clinical studies, as well as in
routine clinical practice, such as
pralidoxime chloride, pralidoxime
methylsulphate, trimedoxime,
obidoxime, and HI-6. Oxime HI-6
was introduced in clinical
practice in Serbia in early 1980s.
It was administered to more than
200 patients (with OP poisoning
and volunteers). A clinical study
with HI-6, administered
intramuscularly at doses up to 500
mg, performed in 22 healthy
volunteers, revealed no adverse
effects, whereas in patients
poisoned by several OP
insecticides, HI-6 ensured fast
reactivation of AChE in almost all
cases except in dimethoate and
phosphamidon poisoning. Contrary
to these findings, the reports
from Asia indicated that
pralidoxime treatment was not
sufficiently effective in their
patients. Despite this controversy
we could still recommend oxime use
in moderate and severe OPI
poisoning. Acute poisoning with
organophosphorus pesticides is not
frequent in Serbia, however, it
represent important clinical
feature due to severity, possible
complications and their impact on
duration and costs of
hospitalization. Initial treatment
involves prevention of further
absorption and provision of
supportive care, followed by
administration of specific
antidotes (carefully titrated
atropine, oxime and diazepam).
New therapeutic regimens:
Many other treatments have been
trialled for use in patients with
acute organophosphorus poisoning
(á-2 adrenergic receptor agonists-clonidine,
butyrylcholinesterase replacement
therapy, extracorporeal blood
purification, including
haemodialysis, haemofiltration,
and haemoperfusion, magnesium
sulphate, oganophosphorus
hydrolases and sodium
bicarbonate), but at present high
quality data are insufficient to
make evidence based
recommendations and further
investigations are necessary.
Brief Biography of the Speaker:
Slavica Vucinic MD PhD is an
associated professor of internal
medicine and clinical toxicology
at the Clinic of Emergency and
Clinical Toxicology of the
National Poison Control Centre,
Military Medical Academy in
Belgrade, Serbia. Her area of
expertise is acute organophosphate
poisoning. Besides being an author
and co-author of 155 papers, she
wrote 6 chapters in different
books of emergency medicine and
one book in the field of clinical
toxicology. She is a Head of two
scientific projects in Military
Medical Academy concerning the
therapy of acute organophosphate
poisoning. She is the Head of the
Clinic of Emergency and Clinical
Toxicology. For the last 7 years
she has been a General Secretary
of Serbian association of
toxicologists. Moreover she is a
member of the European Association
of Poison Control Centres and
Clinical Toxicologists.
|
|